Search CommunityWalk:


Chikujee Therapeutics

18901 Executive Circle Park, Suite 150
Germantown, MD 20874, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Chikujee Therapeutics is a biotech company focused on the development of therapeutic targeted nanobindis to capitalize on the enormous opportunity to dramatically improve on marketed drugs or enable the delivery of novel classes of therapeutics and imaging contrast agents. It was founded in 2008 with a mission to bring together the full range of resources for launching a new product lines that make a difference in people's lives.

Chikujee has developed a revolutionary new technology of creating multifunctional nanoparticles that are suitable for in vivo delivery. The technology NanoBindi, offers the ability to convert insoluble or poorly soluble drugs into delivery vehicles allowing them to become soluble and easier to deliver. Its technology also provides a broad variety of routes of administration including intravenous, intra-arterial, inhalational, topical, and oral. The multifunctional NanoBindis are ideal for detection, monitoring of tumors and delivering drugs to the target site. It's Drugs on Target(TM) technology can be used to deliver a broad range of payloads including emerging therapeutic modalities such as RNAi, allowing it to address multiple therapeutic areas and indications. It is developing ultra sensitive detection probes through its Nidan(TM) platform utilizing its multifunctional nanobindi technology.

Chikujee's key priority is to leverage and exploit the potential for its NanoBindi(TM) based Surface Engineered Nano Probes (SENP) or Target Specific Delivery Vehicles (TSDV) technology, while continuing the discovery and development of new products. It has developed proprietary bionanotechnology based product engine that has broad applications in life-sciences, primarily in biotechnology, biopharmaceutical, and medical devices. The company has developed new Biomolecular Oligomeric Silica hybrid (BOSH) molecules and the TSDV drug delivery platform, a versatile system that addresses the diverse requirements for advanced target specific drug delivery.

Chikujee develops a full spectrum of products used primarily in oncology, cardiovascular diseases and critical care. It has created and developed its first oncology product for the treatment of metastatic breast cancer, using its proprietary nanobindi technology. The company's product pipeline includes: NB-PTXL-DTXL, contains docetaxel indicated for the treatment of prostate cancer, breast cancer, head and neck cancer etc; NB-BCNT and NB-METX, a boron neutron capture therapy product indicated for the treatment of brain tumour; NB-ACS-DTXL and NB-ACS-PTXL indicated for the treatment of cardiovascular diseases etc. It is developing an extensive pipeline of disease specific-contrasting agents for MRI imaging which includes further investigation with paramagnetic particles as well as several other promising iron oxide candidates.

Chikujee has an agreement with Alfagene Biosciences, Inc. to utilize its NanoBindi technology in certain research projects.